CADILLA HEALTHCARE LTD - Q2 FY 21 RESULTS REVIEW -Dt 15 11 2020

 

CADILLA HEALTHCARE LTD

Q2 FY 21 RESULTS  REVIEW

DT 15 11 2020

 

COMPANY OVERVIEW

 

Cadila Healthcare Ltd operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.

Cadila Healthcare is also popularly known as Zydus Cadila. The group is known as Zydus Group and now the company is slowly creating a brand identity for the same. Late Ramanbhai B Patel, a former lecturer at LM College of Pharmacy, had founded Cadila Laboratories in 1952 along with his business partner Indravadan Modi.

The company has in-licensing alliances with global multinationals such as Schering AG, Boehringer Ingelheim, Viatris, etc.

Their product range includes Formulations that cater to various therapeutic areas such as cardiovascular, gastrointestinal, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and nephrology segments and Consumer product division-brands like Sugar Free, Nutralite and Everyuth.

Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

 

Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.

 

MANAGEMENT

Pankaj R Patel            :            Chairman

Sharvil P Patel            :            Managing Director

Ganesh N Nayak         :            Executive Director

 

Cadila Healthcare (in Rs. Cr.)	Sep '20	Jun '20		Sep '19	YOY	QOQ
Total Income	3820	3640		3367	13.5	4.95
P/L Before Exceptional Items & Tax	666		593	390.5	70.6	12.27
Exceptional Items	-132		--	-268.1	-50.76
P/L Before Tax	534.2		593.4	122.4	336.44	-9.98
Tax	110.6		123.5	39.5	180	-10.45
Net Profit	424		470	82.9	410.98	-9.85
Minority Interest	38.4		-32.6	--		-217.79
Share Of P/L Of Associates	11.4		16.7	11.1	2.7	-31.74
Net P/L After M.I & Associates	473.4		454	94	403.62	4.27
Equity Share Capital	102.4		102.4	102.4	0	0
Basic EPS	4.62		4.43	1.05	340	4.29
Raw Materials	920.5	852.3		776.5	18.54	8
Traded Goods	372.8	364.7		395.2	-5.67	2.22
Increase/Decrease in Stocks	29	33.3		-15.2	-290.79	-12.91
Employees Cost	616.5	634.5		596.7	3.32	-2.84
Depreciation	179	176.8		172.3	3.89	1.24
Other Expenses	1,017.80	939.7		987.8	3.04	8.31
P/L Before Other Inc., Int., Excpt. Items & Tax	684.4	638.6		453.3	50.98	7.17
Other Income	27.5	22.5		26.9	2.23	22.22
P/L Before Int., Excpt. Items & Tax	711.9	661.1		480.2	48.25	7.68
Interest	45.7	67.7		89.7	-49.05	-32.5

 

MP  425.6

PE   23

VOLUME                      54,43,702

52 Wk L/H     212.7     451.15  

Market Cap (Rs Cr.)    43,560.25

WEEKLY/MONTHLY 

TECHNICAL RATING

VERY BULLISH

Annual	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Sales	14,253	13,165	11,904	9,376	9,426
Net Profit	1,175	1,851	1,766	1,485	1,921
Other Income	113	201	113	128	115
Total Income	14,367	13,366	12,018	9,504	9,542
Total Expenditure	12,529	10,791	9,596	7,845	7,390
EBIT	1,837	2,575	2,421	1,659	2,151
Interest	341	193	91	44	52
Tax	319	530	564	128	177

      

HISTORICAL PRICES

3YEAR BEF	464
2 YR	357
1 YR	230
3MONTHS	395
1MONTH	438.5
1WEEK	442.35

 

Type	Dividend%	Ex-Dividend date
Interim	350	Mar 23, 2020
Final	350	Jul 25, 2019
Final	350	Jul 31, 2018
Interim	320	Mar 16, 2017
Interim	320	Mar 17, 2016

 

 SPLITS        

Old FV    New FV  Ex-Split

5     1     Oct 06, 2015

 

Share Holding Pattern in (%)
Standalone	Sep-20	Jun-20	Mar-20	Dec-19
Promoters	74.88	74.88	74.88	74.88
Pledged	0	0	0	0
FII/FPI	4.38	4.56	4.41	4.58
Total DII	14.86	14.81	15.12	14.82
Fin.Insts	0.49	3.99	4.26	4.32
Insurance Co	4.58	1.05	1.23	1.14
MF	7.27	7.47	7.33	7.11
Others DIIs	2.52	2.3	2.3	2.25
Others	5.89	5.75	5.59	5.73
Total	100.01	100	100	100.01

 

India : "Pharmacy of the World”.......  is the largest provider of generic drugs globally.

Indian pharmaceutical sector supplies

>50%           Global Demand of Vaccines

>40%           Generic Demand of US Market

~25%           All medicines in the UK